Ask AI
See Activity Collection
ProCE Banner Activity

CAR T-Cell Therapy in Community and Shared-Care Settings: Practical Strategies to Manage Delayed and Long-term Toxicities

Slideset

Downloadable slides on the clinical application and safety management of CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies, with a focus on recognizing and managing acute, delayed, and long-term toxicities in community and shared-care settings. The slides review pivotal clinical trial data supporting approved CAR T-cell therapies for acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma, along with evidence-based strategies for identifying and managing cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, prolonged cytopenias, infections, hypogammaglobulinemia, and delayed neurologic complications. Practical guidance on toxicity monitoring, infection prevention, vaccination, supportive care, patient and caregiver education, and coordination between cellular therapy centers and community oncology teams supports timely intervention and continuity of care following CAR T-cell therapy.

Released: October 27, 2026

Continue Activity

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, TCTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio
Amy Goodrich

Amy Goodrich, CRNP

Nurse Practitioner
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.

Bristol Myers Squibb

Johnson & Johnson

Target Audience

This activity is intended for community oncology nurses, nurse practitioners, clinical nurse specialists, and other healthcare professionals who care for patients treated with CAR T-cell therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Risk-stratify patients receiving CD19- or BCMA-directed CAR T-cell therapy for delayed and long-term toxicities, including prolonged/recurrent cytopenias, infection, hypogammaglobulinemia, delayed neurologic toxicity, HLH/MAS, immune effector cell–associated enterocolitis, and secondary malignancies

  • Differentiate expected post–CAR T-cell recovery from red-flag symptoms or laboratory findings that require urgent evaluation, referral, or re-escalation to the cellular therapy center

  • Apply evidence-informed strategies for post–CAR T-cell therapy monitoring, infection prevention, vaccination counseling, IVIG referral, symptom triage, patient/caregiver education, and documentation

  • Develop a shared-care transition plan that specifies monitoring responsibilities, escalation triggers, emergency department handoff guidance, patient/caregiver education, and communication pathways between the cellular therapy center and community oncology team

Additional Disclosures

Generative artificial intelligence (AI) tools were used for drafting educational content, generating clinical case(s) or scenario(s), and drafting assessment question(s) and/or rationale(s). All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.